Clinical Trials Logo

Aggressive B-cell Lymphomas clinical trials

View clinical trials related to Aggressive B-cell Lymphomas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02205333 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

MEDI6469
Start date: August 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 will be tested with MEDI6469 in a set of subjects with advanced solid tumors while rituximab will be tested with MEDI6469 in subjects with DLBCL. MEDI6469 will be tested as monotherapy in subjects with advanced solid tumors.